MARKET

GNPX

GNPX

Genprex Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.800
-0.070
-2.44%
After Hours: 2.800 0 0.00% 16:00 09/23 EDT
OPEN
2.860
PREV CLOSE
2.870
HIGH
2.920
LOW
2.790
VOLUME
250.57K
TURNOVER
--
52 WEEK HIGH
7.72
52 WEEK LOW
2.240
MARKET CAP
133.08M
P/E (TTM)
-6.5192
1D
5D
1M
3M
1Y
5Y
InvestorNewsBreaks Genprex Inc. (NASDAQ: GNPX) Announces Participation in Two Upcoming Investor Conferences
(MENAFN - Investor Brand Network)
MENAFN · 3d ago
Genprex to Participate in September Investor Conferences
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Var...
Business Wire · 3d ago
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Genprex to Participate in a Monthly CEO Roadshow Webinar Series
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Var...
Business Wire · 07/20 12:30
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
BRIEF-Genprex Announces Initiation Of Its Phase 1/2 Acclaim-1 Clinical Trial For REQORSA Immunogene Therapy
reuters.com · 06/23 13:11
Genprex initiates early-stage REQORSA lung cancer study
Genprex (GNPX) announces initiation of the company's phase 1/2 Acclaim-1 clinical trial for REQORSA immunogene therapy in combination with Tagrisso to treat non-small cell lung cancer following U.S. FDA review.The company
Seekingalpha · 06/23 12:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNPX. Analyze the recent business situations of Genprex Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNPX stock price target is 6.50 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 73
Institutional Holdings: 5.91M
% Owned: 12.43%
Shares Outstanding: 47.53M
TypeInstitutionsShares
Increased
13
914.71K
New
12
486.92K
Decreased
22
2.75M
Sold Out
25
1.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Secretary
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Chief Operating Officer/Executive Vice President
Michael Redman
Executive Vice President/General Counsel
Catherine Vaczy
Independent Director
Brent Longnecker
Independent Director
Jose Moreno Toscano
Independent Director
William Wilson
No Data
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Webull offers kinds of Genprex Inc stock information, including NASDAQ:GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.